Vaccine development for syphilis
Introduction: Syphilis, caused by the spirochete Treponema pallidum subspecies pallidum, continues to be a globally prevalent disease despite remaining susceptible to penicillin treatment. Syphilis vaccine development is a viable preventative approach that will serve to complement public health-orie...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2017-01-01
|
| Series: | Expert Review of Vaccines |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/14760584.2016.1203262 |
| _version_ | 1797680443392262144 |
|---|---|
| author | Karen V. Lithgow Caroline E. Cameron |
| author_facet | Karen V. Lithgow Caroline E. Cameron |
| author_sort | Karen V. Lithgow |
| collection | DOAJ |
| description | Introduction: Syphilis, caused by the spirochete Treponema pallidum subspecies pallidum, continues to be a globally prevalent disease despite remaining susceptible to penicillin treatment. Syphilis vaccine development is a viable preventative approach that will serve to complement public health-oriented syphilis prevention, screening and treatment initiatives to deliver a two-pronged approach to stemming disease spread worldwide. Areas covered: This article provides an overview of the need for development of a syphilis vaccine, summarizes significant information that has been garnered from prior syphilis vaccine studies, discusses the critical aspects of infection that would have to be targeted by a syphilis vaccine, and presents the current understanding within the field of the correlates of protection needed to be achieved through vaccination. Expert commentary: Syphilis vaccine development should be considered a priority by industry, regulatory and funding agencies, and should be appropriately promoted and supported. |
| first_indexed | 2024-03-11T23:30:07Z |
| format | Article |
| id | doaj.art-b7a47d87a2154845b3a9622e62459775 |
| institution | Directory Open Access Journal |
| issn | 1476-0584 1744-8395 |
| language | English |
| last_indexed | 2024-03-11T23:30:07Z |
| publishDate | 2017-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Expert Review of Vaccines |
| spelling | doaj.art-b7a47d87a2154845b3a9622e624597752023-09-20T10:18:01ZengTaylor & Francis GroupExpert Review of Vaccines1476-05841744-83952017-01-01161374410.1080/14760584.2016.12032621203262Vaccine development for syphilisKaren V. Lithgow0Caroline E. Cameron1University of VictoriaUniversity of VictoriaIntroduction: Syphilis, caused by the spirochete Treponema pallidum subspecies pallidum, continues to be a globally prevalent disease despite remaining susceptible to penicillin treatment. Syphilis vaccine development is a viable preventative approach that will serve to complement public health-oriented syphilis prevention, screening and treatment initiatives to deliver a two-pronged approach to stemming disease spread worldwide. Areas covered: This article provides an overview of the need for development of a syphilis vaccine, summarizes significant information that has been garnered from prior syphilis vaccine studies, discusses the critical aspects of infection that would have to be targeted by a syphilis vaccine, and presents the current understanding within the field of the correlates of protection needed to be achieved through vaccination. Expert commentary: Syphilis vaccine development should be considered a priority by industry, regulatory and funding agencies, and should be appropriately promoted and supported.http://dx.doi.org/10.1080/14760584.2016.1203262syphiliscongenital syphilishiv co-infectioncross-protectioncellular immunityhumoral immunitymen who have sex with menvaccine |
| spellingShingle | Karen V. Lithgow Caroline E. Cameron Vaccine development for syphilis Expert Review of Vaccines syphilis congenital syphilis hiv co-infection cross-protection cellular immunity humoral immunity men who have sex with men vaccine |
| title | Vaccine development for syphilis |
| title_full | Vaccine development for syphilis |
| title_fullStr | Vaccine development for syphilis |
| title_full_unstemmed | Vaccine development for syphilis |
| title_short | Vaccine development for syphilis |
| title_sort | vaccine development for syphilis |
| topic | syphilis congenital syphilis hiv co-infection cross-protection cellular immunity humoral immunity men who have sex with men vaccine |
| url | http://dx.doi.org/10.1080/14760584.2016.1203262 |
| work_keys_str_mv | AT karenvlithgow vaccinedevelopmentforsyphilis AT carolineecameron vaccinedevelopmentforsyphilis |